These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33179827)

  • 21. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL; Brown EA; Apetrei E; Bagon J; Calvo C; DeChatel R; Holdaas H; Krcmery S; Kobalava Z;
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enalapril in subantihypertensive dosage attenuates kidney proliferation and functional recovery in normotensive ablation nephropathy of the rat.
    Krivosíková Z; Sebeková K; Spustová V; Lajdová I; Dzúrik R
    Physiol Res; 1999; 48(6):429-35. PubMed ID: 10783907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms.
    Dworkin LD; Benstein JA; Parker M; Tolbert E; Feiner HD
    Kidney Int; 1993 Apr; 43(4):808-14. PubMed ID: 8479116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency.
    Mackie FE; Meyer TW; Campbell DJ
    Kidney Int; 2002 Feb; 61(2):555-63. PubMed ID: 11849396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction.
    Perico N; Zoja C; Corna D; Rottoli D; Gaspari F; Haskell L; Remuzzi G
    Kidney Int; 2009 Nov; 76(9):960-7. PubMed ID: 19625993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
    Krämer S; Loof T; Martini S; Rückert M; Wang Y; Böhler T; Shimizu F; Kawachi H; Neumayer HH; Peters H
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F359-68. PubMed ID: 15769934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TCV-116 inhibits renal interstitial and glomerular injury in glomerulosclerotic rats.
    Shibouta Y; Chatani F; Ishimura Y; Sanada T; Ohta M; Inada Y; Nishikawa K
    Kidney Int Suppl; 1996 Jun; 55():S115-8. PubMed ID: 8743529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthy bone marrow cells reduce progression of kidney failure better than CKD bone marrow cells in rats with established chronic kidney disease.
    van Koppen A; Joles JA; Bongartz LG; van den Brandt J; Reichardt HM; Goldschmeding R; Nguyen TQ; Verhaar MC
    Cell Transplant; 2012; 21(10):2299-312. PubMed ID: 23231961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preservation of renal structure and function in the rat remnant kidney model of chronic renal failure by enalapril treatment.
    Jackson B; Whitty M; Debrevi L; Cubela R
    Pathology; 1987 Jan; 19(1):38-42. PubMed ID: 3035469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of glomerulosclerosis after high-dose enalapril treatment in subtotally nephrectomized rats.
    Adamczak M; Gross ML; Krtil J; Koch A; Tyralla K; Amann K; Ritz E
    J Am Soc Nephrol; 2003 Nov; 14(11):2833-42. PubMed ID: 14569093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of glomerular filtration rate-modifying drugs in the development of anticoagulant-related nephropathy.
    Medipally AK; Xiao M; Rovin BH; Satoskar AA; Ivanov I; Qaisar S; Brodsky SV
    Physiol Rep; 2021 Jan; 9(1):e14697. PubMed ID: 33427414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats.
    Wu-Wong JR; Chen YW; Wessale JL
    Am J Physiol Renal Physiol; 2015 Feb; 308(4):F309-19. PubMed ID: 25503724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-Center Long-Term Follow-Up of Kidney Donors in Argentina (Hospital Italiano de Buenos Aires).
    Mombelli CA; Giordani MC; Imperiali NC; Groppa SR; Villamil Cortez SK; Schreck CM; Rosa-Diez GJ
    Transplant Proc; 2018 Mar; 50(2):418-422. PubMed ID: 29579818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats.
    Wang JL; Cheng HF; Shappell S; Harris RC
    Kidney Int; 2000 Jun; 57(6):2334-42. PubMed ID: 10844603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enalapril versus metoprolol in primary hypertension--effects on the glomerular filtration rate.
    Aurell M; Bengtsson C; Björck S
    Nephrol Dial Transplant; 1997 Nov; 12(11):2289-94. PubMed ID: 9394313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease.
    Ougaard ME; Sembach FE; Jensen HE; Pyke C; Knudsen LB; Kvist PH
    Nephron; 2020; 144(11):595-606. PubMed ID: 32877912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension and renal injury in experimental polycystic kidney disease.
    Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S
    Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy.
    Benigni A; Zoja C; Zatelli C; Corna D; Longaretti L; Rottoli D; Maggioni P; Todeschini M; Noris M; Remuzzi G
    Kidney Int; 2004 Nov; 66(5):1959-65. PubMed ID: 15496167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
    Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
    Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.